Alzinova AB was founded in 2011 by the inventors and MIVAC Development AB in close collaboration with the holding company at the University of Gothenburg in Sweden, GU Ventures AB.

Alzinova AB is engaged in drug discovery research for Alzheimer’s disease. The company’s proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer’s disease research.

More information about Alzinova can be found on the company’s home page (

Contact: Any questions or requests for more information may be directed to Alzinova’s management team at